# Invivyd, Inc.: financial statements, quarterly

IVVD · Nasdaq · CIK 1832038 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ivvd.md) · [Financials](/companies/ivvd/financials.md) · [Filings](/companies/ivvd/filings.md) · [Insiders](/companies/ivvd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ivvd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-126735.md) | [0.0 d](/filings/0000950170-25-042332.md) | [0.0](/filings/0000950170-25-071974.md) | [2.3](/filings/0000950170-25-109029.md) | [9.3](/filings/0001193125-25-268076.md) | [13.8 d](/filings/0001193125-26-092547.md) | [11.3](/filings/0001193125-26-222779.md) | [11.8](/filings/0001193125-26-349215.md) | [13.1](/filings/0001193125-25-268076.md) | [17.2 d](/filings/0001193125-26-092547.md) | [13.7](/filings/0001193125-26-222779.md) | [14.3](/filings/0001193125-26-349215.md) |
| Research and development | $m | [25.6](/filings/0000950170-24-126735.md) | [62.3 d](/filings/0000950170-25-042332.md) | [31.2](/filings/0000950170-25-071974.md) | [30.3](/filings/0000950170-25-109029.md) | [57.9](/filings/0001193125-25-268076.md) | [17.9 d](/filings/0001193125-26-092547.md) | [10.6](/filings/0001193125-26-222779.md) | [9.6](/filings/0001193125-26-349215.md) | [8.0](/filings/0001193125-25-268076.md) | [10.0 d](/filings/0001193125-26-092547.md) | [30.7](/filings/0001193125-26-222779.md) | [29.4](/filings/0001193125-26-349215.md) |
| Selling, general and administrative | $m | [12.9](/filings/0000950170-24-126735.md) | [15.1 d](/filings/0000950170-25-042332.md) | [14.9](/filings/0000950170-25-071974.md) | [21.1](/filings/0000950170-25-109029.md) | [13.0](/filings/0001193125-25-268076.md) | [14.4 d](/filings/0001193125-26-092547.md) | [16.8](/filings/0001193125-26-222779.md) | [16.6](/filings/0001193125-26-349215.md) | [15.0](/filings/0001193125-25-268076.md) | [18.6 d](/filings/0001193125-26-092547.md) | [25.1](/filings/0001193125-26-222779.md) | [29.5](/filings/0001193125-26-349215.md) |
| Operating income | $m | [(43.1)](/filings/0000950170-24-126735.md) | [(76.8) d](/filings/0000950170-25-042332.md) | [(46.1)](/filings/0000950170-25-071974.md) | [(49.2)](/filings/0000950170-25-109029.md) | [(62.3)](/filings/0001193125-25-268076.md) | [(19.2) d](/filings/0001193125-26-092547.md) | [(16.9)](/filings/0001193125-26-222779.md) | [(15.1)](/filings/0001193125-26-349215.md) | [(11.0)](/filings/0001193125-25-268076.md) | [(12.6) d](/filings/0001193125-26-092547.md) | [(43.1)](/filings/0001193125-26-222779.md) | [(45.8)](/filings/0001193125-26-349215.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126735.md) | [0.0 d](/filings/0000950170-25-042332.md) | [0.0](/filings/0000950170-25-071974.md) | [0.0](/filings/0000950170-24-096674.md) | [0.0](/filings/0001193125-25-268076.md) | [0.0 d](/filings/0001193125-26-092547.md) | [0.0](/filings/0001193125-26-222779.md) | [0.0](/filings/0001193125-26-349215.md) | [0.0](/filings/0001193125-25-268076.md) | [0.0 d](/filings/0001193125-26-092547.md) | [0.0](/filings/0001193125-26-222779.md) | [0.0](/filings/0001193125-26-349215.md) |
| Net income | $m | [(39.4)](/filings/0000950170-24-126735.md) | [(73.7) d](/filings/0000950170-25-042332.md) | [(43.5)](/filings/0001193125-25-268076.md) | [(47.2)](/filings/0001193125-25-268076.md) | [(60.7)](/filings/0001193125-25-268076.md) | [(18.4) d](/filings/0001193125-26-092547.md) | [(16.3)](/filings/0001193125-26-349215.md) | [(14.7)](/filings/0001193125-26-349215.md) | [(10.5)](/filings/0001193125-25-268076.md) | [(11.1) d](/filings/0001193125-26-092547.md) | [(41.4)](/filings/0001193125-26-349215.md) | [(44.4)](/filings/0001193125-26-349215.md) |
| Diluted EPS | $ per share | [(0.36)](/filings/0000950170-24-126735.md) | not reported | [(0.38)](/filings/0000950170-25-071974.md) | [(0.40)](/filings/0000950170-25-109029.md) | [(0.51)](/filings/0001193125-25-268076.md) | not reported | [(0.14)](/filings/0001193125-26-222779.md) | [(0.12)](/filings/0001193125-26-349215.md) | [(0.06)](/filings/0001193125-25-268076.md) | not reported | [(0.13)](/filings/0001193125-26-222779.md) | [(0.14)](/filings/0001193125-26-349215.md) |
| Basic EPS | $ per share | [(0.36)](/filings/0000950170-24-126735.md) | not reported | [(0.38)](/filings/0000950170-25-071974.md) | [(0.40)](/filings/0000950170-25-109029.md) | [(0.51)](/filings/0001193125-25-268076.md) | not reported | [(0.14)](/filings/0001193125-26-222779.md) | [(0.12)](/filings/0001193125-26-349215.md) | [(0.06)](/filings/0001193125-25-268076.md) | not reported | [(0.13)](/filings/0001193125-26-222779.md) | [(0.14)](/filings/0001193125-26-349215.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [182](/filings/0000950170-23-062043.md) | [201](/filings/0000950170-25-042332.md) | [189](/filings/0000950170-24-057017.md) | [148](/filings/0000950170-24-096674.md) | [107](/filings/0000950170-24-126735.md) | [69.3](/filings/0001193125-26-092547.md) | [48.1](/filings/0000950170-25-071974.md) | [34.9](/filings/0000950170-25-109029.md) | [85.0](/filings/0001193125-25-268076.md) | [227](/filings/0001193125-26-349215.md) | [184](/filings/0001193125-26-222779.md) | [160](/filings/0001193125-26-349215.md) |
| Current assets | $m | [270](/filings/0000950170-23-062043.md) | [225](/filings/0000950170-25-042332.md) | [210](/filings/0000950170-24-057017.md) | [173](/filings/0000950170-24-096674.md) | [151](/filings/0000950170-24-126735.md) | [101](/filings/0001193125-26-092547.md) | [75.8](/filings/0000950170-25-071974.md) | [59.3](/filings/0000950170-25-109029.md) | [110](/filings/0001193125-25-268076.md) | [247](/filings/0001193125-26-349215.md) | [205](/filings/0001193125-26-222779.md) | [182](/filings/0001193125-26-349215.md) |
| Total assets | $m | [275](/filings/0000950170-23-062043.md) | [229](/filings/0000950170-25-042332.md) | [215](/filings/0000950170-24-057017.md) | [177](/filings/0000950170-24-096674.md) | [162](/filings/0000950170-24-126735.md) | [130](/filings/0001193125-26-092547.md) | [104](/filings/0000950170-25-071974.md) | [89.1](/filings/0000950170-25-109029.md) | [139](/filings/0001193125-25-268076.md) | [277](/filings/0001193125-26-349215.md) | [242](/filings/0001193125-26-222779.md) | [219](/filings/0001193125-26-349215.md) |
| Current liabilities | $m | [26.8](/filings/0000950170-23-062043.md) | [50.3](/filings/0000950170-25-042332.md) | [36.3](/filings/0000950170-24-057017.md) | [36.7](/filings/0000950170-24-096674.md) | [78.5](/filings/0000950170-24-126735.md) | [62.0](/filings/0001193125-26-092547.md) | [49.6](/filings/0000950170-25-071974.md) | [44.5](/filings/0000950170-25-109029.md) | [44.5](/filings/0001193125-25-268076.md) | [34.2](/filings/0001193125-26-349215.md) | [31.7](/filings/0001193125-26-222779.md) | [31.0](/filings/0001193125-26-349215.md) |
| Total liabilities | $m | [28.4](/filings/0000950170-23-062043.md) | [51.7](/filings/0000950170-25-042332.md) | [37.0](/filings/0000950170-24-057017.md) | [36.7](/filings/0000950170-24-096674.md) | [78.8](/filings/0000950170-24-126735.md) | [62.0](/filings/0001193125-26-092547.md) | [49.6](/filings/0000950170-25-071974.md) | [46.3](/filings/0000950170-25-109029.md) | [46.1](/filings/0001193125-25-268076.md) | [35.3](/filings/0001193125-26-349215.md) | [38.7](/filings/0001193125-26-222779.md) | [37.8](/filings/0001193125-26-349215.md) |
| Shareholders' equity | $m | [246](/filings/0000950170-24-126735.md) | [177](/filings/0001193125-26-092547.md) | [178](/filings/0001193125-25-268076.md) | [141](/filings/0001193125-25-268076.md) | [83.2](/filings/0001193125-25-268076.md) | [67.5](/filings/0001193125-26-349215.md) | [54.1](/filings/0001193125-26-349215.md) | [42.8](/filings/0001193125-26-349215.md) | [93.1](/filings/0001193125-25-268076.md) | [242](/filings/0001193125-26-349215.md) | [203](/filings/0001193125-26-349215.md) | [181](/filings/0001193125-26-349215.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(35.4) d](/filings/0000950170-24-126735.md) | [(59.2) d](/filings/0000950170-25-042332.md) | [(50.2)](/filings/0000950170-25-071974.md) | [(41.6) d](/filings/0000950170-25-109029.md) | [(41.1) d](/filings/0001193125-25-268076.md) | [(37.6) d](/filings/0001193125-26-092547.md) | [(21.1)](/filings/0001193125-26-222779.md) | [(13.3) d](/filings/0001193125-26-349215.md) | [(8.3) d](/filings/0001193125-25-268076.md) | [(15.5) d](/filings/0001193125-26-092547.md) | [(41.7)](/filings/0001193125-26-222779.md) | [(43.0) d](/filings/0001193125-26-349215.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-126735.md) | [0.0 d](/filings/0000950170-25-042332.md) | [0.1](/filings/0000950170-25-071974.md) | [0.0 d](/filings/0000950170-25-109029.md) | [0.0 d](/filings/0001193125-25-268076.md) | [(0.0) d](/filings/0001193125-26-092547.md) | [0.1](/filings/0001193125-26-222779.md) | [0.0 d](/filings/0001193125-26-349215.md) | [0.0 d](/filings/0001193125-25-268076.md) | [0.0 d](/filings/0001193125-26-092547.md) | [0.7](/filings/0001193125-26-222779.md) | [0.5 d](/filings/0001193125-26-349215.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-126735.md) | [0.0 d](/filings/0000950170-25-042332.md) | not reported | not reported | [0.0 d](/filings/0000950170-24-126735.md) | [0.0 d](/filings/0000950170-25-042332.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [108](/filings/0000950170-23-062043.md) | [109](/filings/0000950170-24-057017.md) | [109](/filings/0000950170-24-096674.md) | [110](/filings/0000950170-24-126735.md) | [116](/filings/0000950170-25-071974.md) | [119](/filings/0000950170-25-109029.md) | [119](/filings/0001193125-25-268076.md) | [120](/filings/0001193125-26-222779.md) | [120](/filings/0001193125-26-349215.md) | [170](/filings/0001193125-25-268076.md) | [310](/filings/0001193125-26-222779.md) | [320](/filings/0001193125-26-349215.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 294,758,746 at 2026-07-30, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349215.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.